fluticasone (cutivate) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fluticasone furoate, sold under the brand name Flonase Sensimist among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray. It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol. Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0810 - $294.4900

Australia

$5.7450 - $26.3369
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( fluticasone (cutivate), salmeterol (serevent) - other names: advair hfa, airduo digihaler, airduo respiclick, fluticasone propionate/salmeterol (fs), wixela inhub )
|
( fluticasone (cutivate), vilanterol (Anoro Elipta) - other name: fluticasone furoate / vilanterol trifenatate 100/25 mcg )
|
( azelastine (astelin), fluticasone (cutivate) - other name: fluticasone nasal 50 mcg/inh nasal spray, azelastine nasal 140 mcg/inh nasal spray )
|
( fluticasone (cutivate), umeclidinium (incruse ellipta), vilanterol (Anoro Elipta) )

Alternative names

adoair250 | advair diskus | aerivio spiromax | airflusal forspiro | avamys | cci18781 | cci-18781 | cultivate | cutivate | flixonase | flixotide | flonase | flovent | flovent diskus 100 | flovent diskus 250 | flovent diskus 50 | flovent hfa | fluticasone | fluticasone 17-propionate | fluticasone-formoterol | fluticasone fuorate | fluticasone furoate | fluticasone furoate / umeclidinium bromide / vilanterol trifenatate | fluticasone furoate, umeclidinium bromide, vilanterol trifenatate | fluticasone furoate / vilanterol | fluticasone furoate / vilanterol trifenatate | fluticasone propionate | fluticasone proprionate | fluticasonum furoas | flutiform | furoate de fluticasone | furoato de fluticasona | gw685698 | gw685698x | msrd-100 | nasofan | pf-04764793 | pirinase | salmeterol / fluticasone propionate | salmeterol xinafoate / fluticasone propionate | sereflo | seretide | seretide 100 | seretide 125 | seretide 250 | seretide 50 | seretide 500 | sirdupla | tv48108 | veramyst | vr506

Organizations (368)

Research & Development (356)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (21)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (78)

Approved Indications (9)


 

Asthma

Bronchitis, Chronic

Dermatitis, Atopic

Emphysema

Pulmonary Disease, Chronic Obstructive

Rhinitis, Allergic (approved 2007)

Rhinitis, Allergic, Seasonal

Skin Diseases

Skin Diseases, Eczematous (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (77)


 

Abdominal Injuries (Phase 2)

Adipose Tissue (Phase 2)

Airway Obstruction (Phase 4)

Allergy and Immunology (Phase 4)

Arthritis, Rheumatoid (Phase 1)

Asthma ()

Asthma, Exercise-Induced (Phase 3)

Biological Availability (Phase 1)

Blepharitis (Phase 2)

Body Contouring (Phase 2)

Body Weight (Phase 2)

Bronchial Spasm (Phase 4)

Bronchiectasis (Phase 4)

Bronchiolitis (Phase 2)

Bronchiolitis Obliterans (Phase 3)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Candidiasis, Oral (Phase 4)

Carcinoma, Bronchogenic (Phase 2)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

COVID-19 (Phase 3)

Croup (Phase 3)

Deglutition Disorders (Phase 3)

Depression (Phase 4)

Dermatitis, Allergic Contact (Phase 2/Phase 3)

Dermatitis, Atopic ()

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Early Phase 1)

Drug Evaluation (Phase 4)

Drugs, Investigational (Phase 1/Phase 2)

Eczema (Phase 1/Phase 2)

Emphysema (Phase 4)

Eosinophilic Esophagitis (Phase 4)

Eosinophils (Phase 2/Phase 3)

Esophagitis (Phase 2)

Eustachian Tube (Phase 2)

Exercise (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 4)

Hematopoietic Stem Cell Transplantation (Phase 3)

Hypersensitivity (Phase 4)

Hypertension (Phase 1)

Hypertrophy (Phase 4)

Inflammation (Phase 2/Phase 3)

Intestinal Neoplasms (Phase 2/Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Nasal Polyps (Phase 4)

Ocular Hypertension (Phase 4)

Osteoarthritis, Knee (Phase 2)

Otitis Media with Effusion (Phase 4)

Pharmacokinetics (Phase 2)

Pseudomonas aeruginosa (Phase 2)

Pseudomonas Infections (Phase 2)

Psoriasis (Phase 4)

Pulmonary Disease, Chronic Obstructive ()

Quality of Life (Phase 4)

Respiratory Sounds (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

Rhinitis, Vasomotor (Phase 3)

Sinusitis (Phase 3)

Skin Diseases (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Steroids (Phase 4)

Tachyphylaxis (Phase 4)

Therapeutic Equivalency (Phase 1)

Thyroid Gland (Phase 2)

Urinary Tract Infections (Phase 2)

Vitiligo (Phase 4)

Vocal Cord Dysfunction (Phase 1)

Voice Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 717
  • # of Trial Organizations: 356

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue